Highest-materiality recent filing
Marpai Q3 operating expenses down 24% YoY to $3.8M; net loss narrows to $3.5M
Operating expenses decreased 24% YoY from $5.0M to $3.8M for Q3 2025.
Marpai raises ~$1.1M in private placement; CEO's entity buys 86% of shares
Issued 1,038,519 shares at $1.0592/share in unregistered private placement to three investors.
Marpai Q2 2025: net loss cut 66% to $4.4M; op ex down 70%; CEO targets Q1 2026 profitability
Operating expenses fell 70% ($9.9M savings) to $3.6M; operating loss reduced 71% to $3.6M.
Marpai raises ~$650k in private placement; CEO entity buys 371k shares
Sold 603,640 shares of Class A common stock at $1.0768/share for aggregate proceeds of ~$650,000.
Marpai Q1 2025 revenue $5.4M down 27% YoY; operating loss narrows 45% to $2.3M
Net revenue $5.4M, down $2.0M (27%) vs Q1 2024; operating expenses cut 33% to $7.7M.
Marpai Q4 net loss improves 67.5% YoY; full-year adjusted EBITDA loss narrows to $9.1M
Q4 net revenue $6.6M, down 6% sequentially; operating loss $2.7M, improved 12.2% from Q3.
Marpai reduces Base Purchase amounts by $3M with AXA; new payment schedule through 2027
Reduction criteria met as of Dec 31, 2024: largest shareholder contributed ≥$3M, listing maintained, timely payments.
Marpai secures $5M additional non-dilutive debt financing from JGB
Additional $5M financing from JGB Collateral LLC via senior secured debentures (principal $5.376M).
Marpai raises ~$1.3M via private placement of 2.7M shares at $0.481; CEO affiliate participates
Issued 2,702,702 shares at $0.481 per share, raising approximately $1.3 million.
Marpai Q2 net loss widens to $13M on $7.6M goodwill impairment; revenue drops 28%
Net revenues $7.2M, down 28% YoY from $10.1M in Q2 2023.
Marpai withdraws from Nasdaq hearings, expects delisting on May 29; trading to move to OTCQX
Marpai was not compliant with Nasdaq minimum stockholders' equity requirement under Rule 5550(b)(1).
Marpai Q1 2024 net revenues $7.4M (-24% YoY); net loss improves 51% to $4.3M
Net revenues $7.4M, down 24% YoY; gross profit $2.5M (-23% YoY).
Marpai issues $11.83M convertible debentures; net proceeds $11M; conversion $3.00/share
Aggregate principal $11.83M; purchase price $11M; OID of $830,000.
Marpai Q4 2023 net revenues $8.7M up 14% YoY; net loss improved to $5.0M
Q4 net revenues $8.7M, up 14% YoY; gross profit $3.0M, up 6.5%.
Nasdaq panel grants Marpai extension to May 28 to meet $35M MVLS listing requirement
Nasdaq Hearings Panel granted extension until May 28, 2024 to regain compliance with MVLS minimum of $35M.
Marpai issues 910k shares at $1.65 to CEO-affiliated fund in private placement
Sold 910,000 Class A common shares to HillCour Investment Fund LLC (CEO Damien Lamendola controls) at $1.65/share.
Marpai reports preliminary Q4 revenue up 14% YoY, operating loss improves $5M
Q4 2023 net revenue ~$8.7M (+14% YoY); FY2023 ~$37.2M (+53% YoY).
Marpai reports preliminary Q4 2023 revenue $8.7M (+14% YoY), operating loss improves $5M
Q4 2023 net revenues ~$8.7M, up ~14% from Q4 2022; FY 2023 net revenues ~$37.2M, up ~53% YoY.
On May 13, 2025, the Board of Directors of Marpai, Inc. (the “Company”) appointed Dallas Scrip, age 42, as Chief Operating Officer of the Company, effective as of June 2, 2025.
On May 12, 2024, Mike Dendy notified the board of directors (the “Board”) of Marpai, Inc. (the “Company”) of his resignation from the Board, effective immediately.
Max materiality 0.80 · Median 0.57 · Most common event other_material